Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial

Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 531;
Michael Hofman
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Violet
3Radiation Oncology Peter MacCalllum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahneen Sandhu
2Medical Oncology Peter MacCalllum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin Ferdinandus
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sue Ping Thang
6Department of Nuclear Medicine and PET Singapore General Hospital Singapore Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amir Iravani
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grace Kong
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aravind Ravi Kumar
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Akhurst
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Price Jackson
5Medical Physics Peter MacCallum Cancer Centre Melbourne Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Scalzo
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Williams
3Radiation Oncology Peter MacCalllum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodney Hicks
4Centre for Molecular Imaging Peter MacCallum Cancer Centre Melbourne VIC Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Information

vol. 59 no. supplement 1 531

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 23, 2018.

Copyright & Usage 
© 2018

Author Information

  1. Michael Hofman1,
  2. John Violet3,
  3. Shahneen Sandhu2,
  4. Justin Ferdinandus1,
  5. Sue Ping Thang6,
  6. Amir Iravani1,
  7. Grace Kong1,
  8. Aravind Ravi Kumar1,
  9. Tim Akhurst1,
  10. Price Jackson5,
  11. Mark Scalzo1,
  12. Scott Williams3 and
  13. Rodney Hicks4
  1. 1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
  2. 2Medical Oncology Peter MacCalllum Cancer Centre Melbourne VIC Australia
  3. 3Radiation Oncology Peter MacCalllum Cancer Centre Melbourne VIC Australia
  4. 4Centre for Molecular Imaging Peter MacCallum Cancer Centre Melbourne VIC Australia
  5. 5Medical Physics Peter MacCallum Cancer Centre Melbourne Australia
  6. 6Department of Nuclear Medicine and PET Singapore General Hospital Singapore Singapore

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2018 to April 2025

AbstractFullPdf
May 2018400
Jun 201833200
Jul 201832400
Aug 201812700
Sep 20188800
Oct 201820100
Nov 201811300
Dec 20186400
Jan 201913300
Feb 201912900
Mar 20198400
Apr 20196600
May 20198300
Jun 20198300
Jul 201911200
Aug 20195500
Sep 20199000
Oct 20196700
Nov 20198600
Dec 20193700
Jan 20204000
Feb 20205900
Mar 20204100
Apr 20205900
May 20203400
Jun 20205800
Jul 20203400
Aug 20205100
Sep 20204600
Oct 20206300
Nov 20205100
Dec 20203300
Jan 20213800
Feb 20212800
Mar 20215700
Apr 20215000
May 20212600
Jun 20214200
Jul 20214800
Aug 20214300
Sep 20213200
Oct 20214700
Nov 202111100
Dec 20216400
Jan 20227900
Feb 20225700
Mar 20228000
Apr 20224500
May 20225300
Jun 20221600
Jul 20222300
Aug 20222400
Sep 20222600
Oct 20223200
Nov 20222400
Dec 20221600
Jan 20232300
Feb 20231400
Mar 20232600
Apr 20232500
May 20231300
Jun 20232600
Jul 20232200
Aug 20233000
Sep 20232600
Oct 20234100
Nov 20231700
Dec 20234200
Jan 20246200
Feb 20242700
Mar 20241500
Apr 20242000
May 20242400
Jun 20241900
Jul 20245100
Aug 20242100
Sep 20242800
Oct 20241700
Nov 20242300
Dec 20242100
Jan 20253000
Feb 20253500
Mar 20252900
Apr 20257600
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial
Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Price Jackson, Mark Scalzo, Scott Williams, Rodney Hicks
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 531;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial
Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Price Jackson, Mark Scalzo, Scott Williams, Rodney Hicks
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 531;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • 177Lu-PSMA Therapy
  • Nuclear Medicine and Wall Street: An Evolving Relationship
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of SUVmax
Show more Oncology, Clinical Diagnosis Track

Prostate: Therapy

  • Discrete evaluation of multi-cycle Lu-177-PSMA-617-therapy effects on bone versus lymph node metastases in patients with metastasized castration‑resistant prostate cancer (mCRPC)
  • Initial experience with 225Ac-PSMA-617 in patients with advanced-stage prostate cancer
  • Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA617: Dosimetry, toxicity and duration of tumor-control.
Show more Prostate: Therapy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire